In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Digital Health

Set Alert for Digital Health

Will Advanced Technology Simulations Lead To More And Better Drugs? Start-Up Schrodinger Says It Can

Schrodinger LLC is a leading player in the emerging high-stakes field of computational chemical simulation software to boost the quality and productivity of drug discovery and lead generation. Its business model relies heavily on validating theoretical concepts of science and engineering in real-world settings through partnerships with a blue-chip list of pharma and biotech companies.

Digital Health Innovation BioPharmaceutical

Digital Deals And Life Sciences: Avoiding Death By A Thousand Pilots

EY executive survey yields insights into how digital technology is helping drive biopharma deal strategy and aiding companies to meet competitive challenges.

Digital Health Deals Market Intelligence
Advertisement

Winners Are Beginning To Emerge In Digital Health – But Without Planning Medtechs Risk Missing The Boat

The leading medtechs are starting to develop models for providers that show how to implement successful digital strategies, a trend that is serving to put pressure on companies that are yet to make a commitment, says ZS Associates' Pete Masloski.

 

Market Access Digital Health Medical Device

Data And The Digital Horizon: Perspective From The Agency C-suite

While digital health applications represent a major opportunity for biopharma, acting on the premise – and realizing its promise – depends on quantum-level shifts in organizational design and cultural resilience to disruptive change.  In an In Vivo interview, Omnicom Health Group’s SVP for Data Solutions Christina Kim says industry progress toward a digitized future varies, but the necessity to act is clear. 

Digital Health Business Strategies Innovation

Doubling Pharma Value With Data Science

A once-in-a-generation opportunity has opened to digitally redesign a core part of the biopharma business. Capturing the opportunity requires vision and leadership; it’s not about the technology.

Digital Health Business Strategies Market Access

GE Healthcare’s New Value Proposition: The Strategic Language Of Software

For an industry whose central structural dilemma is the slow pace of progress from bench to bedside, GE stands out as an exemplar of success – its performance on speed-to-market product launch has been studied extensively by big pharma strategists. GE Healthcare’s Tom McGuinness tells In Vivo how his division is doubling down on this record, using software and data analytics to help biopharma become more efficient in moving products to patients.

BioPharmaceutical Business Strategies Leadership

More on Digital Health from Scrip, Pink Sheet & Medtech Insight.

Roche Pushes Personalization With $2.4Bn Foundation Buy-Out

By picking up the rest of Foundation Medicine, which is now valued at $5.3bn, the Swiss giant is expanding its leadership in cancer diagnostics, genomics and molecular information for personal medicine.

M & A Digital Health

Size Doesn't Matter: US FDA Refines Dig-Health Pre-Cert Model

After receiving feedback from industry and other stakeholders, FDA has revised its "working model" for its planned pre-certification program for health software. It now states that size of a company will not preclude them from participating in the program. The agency has also refined how it will conduct appraisals.

Regulation Digital Health

US FDA’s Patient Input Guidance Opens Door Wider To Social Media Data Collection

Following stakeholder criticism of an earlier discussion paper, draft guidance does not automatically foreclose use of social media data as the primary source of qualitative research; however, agency says entities submitting such data for regulatory review must ensure rigor in methodology and data integrity.

Clinical Trials Drug Approval Standards

Roche Pushes Personalization With $2.4bn Foundation Buy-Out

By picking up the rest of Foundation Medicine, which is now valued at $5.3bn, the Swiss giant is expanding its leadership in cancer diagnostics, genomics and molecular information for personal medicine.

M & A Cancer

Medicaid Targeting Telemedicine To Address Opioid Crisis

CMS sent guidance to state Medicaid directors on how to leverage federal funding authorities for telehealth counseling and gain reimbursement for remote monitoring programs to aid beneficiaries struggling with opioid substance abuse.

Reimbursement Policy

Scrip Asks... What Is The Future Of Biotech?

Scrip asked industry leaders during the BIO 2018 meeting to envision future changes to the rapidly evolving world of biotechnology, predicting what the next five years will bring. 

Innovation Business Strategies
See All
UsernamePublicRestriction

Register